Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $52000.0.

  • Praxis Precision Medicines' Gains from Investment Securities rose 510000.0% to $52000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 81474.36%. This contributed to the annual value of $308000.0 for FY2024, which is 12481.75% up from last year.
  • According to the latest figures from Q3 2025, Praxis Precision Medicines' Gains from Investment Securities is $52000.0, which was up 510000.0% from $23000.0 recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Gains from Investment Securities ranged from a high of $1.2 million in Q1 2025 and a low of $1000.0 during Q3 2023
  • Over the past 4 years, Praxis Precision Medicines' median Gains from Investment Securities value was $16000.0 (recorded in 2022), while the average stood at $131666.7.
  • As far as peak fluctuations go, Praxis Precision Medicines' Gains from Investment Securities crashed by 8571.43% in 2023, and later soared by 510000.0% in 2025.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' Gains from Investment Securities stood at $7000.0 in 2022, then fell by 28.57% to $5000.0 in 2023, then surged by 3040.0% to $157000.0 in 2024, then crashed by 66.88% to $52000.0 in 2025.
  • Its Gains from Investment Securities stands at $52000.0 for Q3 2025, versus $23000.0 for Q2 2025 and $1.2 million for Q1 2025.